177 related articles for article (PubMed ID: 18691149)
1. Azathioprine in multiple sclerosis.
Invernizzi P; Benedetti MD; Poli S; Monaco S
Mini Rev Med Chem; 2008 Aug; 8(9):919-26. PubMed ID: 18691149
[TBL] [Abstract][Full Text] [Related]
2. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.
Kalincik T; Horakova D; Spelman T; Jokubaitis V; Trojano M; Lugaresi A; Izquierdo G; Rozsa C; Grammond P; Alroughani R; Duquette P; Girard M; Pucci E; Lechner-Scott J; Slee M; Fernandez-Bolanos R; Grand'Maison F; Hupperts R; Verheul F; Hodgkinson S; Oreja-Guevara C; Spitaleri D; Barnett M; Terzi M; Bergamaschi R; McCombe P; Sanchez-Menoyo J; Simo M; Csepany T; Rum G; Boz C; Havrdova E; Butzkueven H;
Ann Neurol; 2015 Mar; 77(3):425-35. PubMed ID: 25546031
[TBL] [Abstract][Full Text] [Related]
3. Multiple sclerosis: closing in on an oral treatment.
Martin R
Nature; 2010 Mar; 464(7287):360-2. PubMed ID: 20237554
[No Abstract] [Full Text] [Related]
4. Compared benefit of approved and experimental immunosuppressive therapeutic approaches in multiple sclerosis.
Gonsette RE
Expert Opin Pharmacother; 2007 Jun; 8(8):1103-16. PubMed ID: 17516874
[TBL] [Abstract][Full Text] [Related]
5. Early switch to fingolimod may decrease the risk of disease recurrence after natalizumab interruption.
Laroni A; Brogi D; Milesi V; Abate L; Uccelli A; Mancardi G
Mult Scler; 2013 Aug; 19(9):1236-7. PubMed ID: 23184503
[No Abstract] [Full Text] [Related]
6. Therapeutic interference with leukocyte recirculation in multiple sclerosis.
Sellebjerg F; Sørensen PS
Eur J Neurol; 2015 Mar; 22(3):434-42. PubMed ID: 25582213
[TBL] [Abstract][Full Text] [Related]
7. Comment on 'Fingolimod to treat severe MS after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?' Maillart et al.
Tur C; Montalban X
Mult Scler; 2014 Apr; 20(4):510-1. PubMed ID: 24468818
[No Abstract] [Full Text] [Related]
8. Previous treatment influences fingolimod efficacy in relapsing-remitting multiple sclerosis: results from an observational study.
Baldi E; Guareschi A; Vitetta F; Senesi C; Curti E; Montepietra S; Simone AM; Immovilli P; Caniatti L; Tola MR; Pesci I; Montanari E; Sola P; Granella F; Motti L; Ferraro D
Curr Med Res Opin; 2014 Sep; 30(9):1849-55. PubMed ID: 24831186
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
Calabresi PA; Radue EW; Goodin D; Jeffery D; Rammohan KW; Reder AT; Vollmer T; Agius MA; Kappos L; Stites T; Li B; Cappiello L; von Rosenstiel P; Lublin FD
Lancet Neurol; 2014 Jun; 13(6):545-56. PubMed ID: 24685276
[TBL] [Abstract][Full Text] [Related]
10. Novel therapeutic approaches to autoimmune demyelinating disorders.
Sanvito L; Constantinescu CS; Gran B
Curr Pharm Des; 2011; 17(29):3191-201. PubMed ID: 21864270
[TBL] [Abstract][Full Text] [Related]
11. Effects of fingolimod in relapsing-remitting multiple sclerosis.
Sorensen PS
Lancet Neurol; 2014 Jun; 13(6):526-7. PubMed ID: 24685277
[No Abstract] [Full Text] [Related]
12. Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis.
Sørensen PS
J Neurol Sci; 2011 Dec; 311 Suppl 1():S29-34. PubMed ID: 22206763
[TBL] [Abstract][Full Text] [Related]
13. [Current treatment of multiple sclerosis].
Csépány T
Lege Artis Med; 2011 Feb; 21(2):97-104. PubMed ID: 21710707
[TBL] [Abstract][Full Text] [Related]
14. Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis.
Havla J; Tackenberg B; Hellwig K; Meinl I; Krumbholz M; Seitz F; Eienbröker C; Gold R; Hohlfeld R; Kleiter I; Kümpfel T
J Neurol; 2013 May; 260(5):1382-7. PubMed ID: 23266894
[TBL] [Abstract][Full Text] [Related]
15. Background and rationale for mechanism of action, efficacy, and safety of fingolimod (Gilenya), the first oral therapy for remitting-relapsing multiple sclerosis: with special emphasis upon visual safety.
Huggins A; Sergott RC
Curr Opin Ophthalmol; 2011 Nov; 22(6):447-50. PubMed ID: 21946305
[No Abstract] [Full Text] [Related]
16. Cost minimisation analysis of fingolimod vs natalizumab as a second line of treatment for relapsing-remitting multiple sclerosis.
Crespo C; Izquierdo G; García-Ruiz A; Granell M; Brosa M
Neurologia; 2014 May; 29(4):210-7. PubMed ID: 24161412
[TBL] [Abstract][Full Text] [Related]
17. [Dilemma of further therapeutic step in remitting-relapsing multiple sclerosis in case of ineffectiveness of first-line treatment: fingolimod or natalizumab?].
Gábor L
Ideggyogy Sz; 2014 Mar; 67(3-4):141. PubMed ID: 26118259
[No Abstract] [Full Text] [Related]
18. Are natalizumab and fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study.
Gajofatto A; Bianchi MR; Deotto L; Benedetti MD
Eur Neurol; 2014; 72(3-4):173-80. PubMed ID: 25226868
[TBL] [Abstract][Full Text] [Related]
19. [Multiple sclerosis: beyong first line therapies].
Schluep M; Du Pasquier R
Rev Med Suisse; 2012 May; 8(339):946-9. PubMed ID: 22675826
[TBL] [Abstract][Full Text] [Related]
20. Managing MS in a changing treatment landscape.
Duddy M; Haghikia A; Cocco E; Eggers C; Drulovic J; Carmona O; Zéphir H; Gold R
J Neurol; 2011 May; 258(5):728-39. PubMed ID: 21437661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
